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Abstract: Central serous chorioretinopathy (CSC) is a common retina disease and has
a relative high recurrence rate, etiology, and pathogenesis of which remains largely ambig-
uous. The effects on the retina are usually self-limited, although some people are left with
permanent vision loss due to progressive and irreversible photoreceptor damage or retinal
pigment epithelium atrophy. There have been a number of interventions used in CSC,
including, but not limited to, laser treatment, photodynamic therapy (PDT), intravitreal
injection of anti-vascular endothelial growth factor agents, and subthreshold lasers. It is
not clear whether there is a clinically important benefit to treating acute CSC, which often
resolves spontaneously as part of its natural history. Of the interventions studied to date, PDT
and micropulse laser treatment appear the most promising.
Keywords: central serous chorioretinopathy, acute central serous chorioretinopathy, chronic
central serous chorioretinopathy
Introduction
Central serous chorioretinopathy (CSC) was first identified and described in 1866
by von Graefe, who referred to the disease as “recurrent central retinitis.”
It is a common ocular disease characterized by decompensation of the retinal
pigment epithelium (RPE), which results in neurosensory retinal detachment, serous
pigment epithelium detachment (PED), and RPE atrophy. It is usually unilateral and
predominantly affects young or middle-aged (25 to 50 years) adults, with men
being affected more frequently than women.1
In its typical presentation, CSC appears as a localized serous detachment of the
neurosensory retina involving the region of the macula without subretinal blood or
lipid exudates. The margins of the serous detachment are sloping and merge
gradually into the normally attached retina of the posterior pole. Occasionally, it
is associated with a single or multiple serous PED.
Patients affected by CSC often complain of blurred vision (usually only in one eye),
typically perceived as a dark spot or scotoma in the central visual field, with associated
image distortion (metamorphopsia). Other common symptoms includemicropsia (reduc-
tion of the apparent size of objects), mild dischromatopsia (abnormal color perception),
and reduced contrast sensitivity. However, CSC may also be asymptomatic.2
The visual acuity of people affected by CSC varies widely; Amsler grid testing
reveals distortion of the straight lines, which may appear blurred due to a central
scotoma. A small relative defect of the afferent pupillary reflex is also occasionally
present.
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Disease Course and Prognosis
The natural course of CSC is often self-limiting, and
spontaneous resolution and complete fluid reabsorption
often occurs. The visual prognosis is good in 90–95% of
cases and visual acuity returns to normal within a few
months once the fluid has resolved. The visual distortion
often reduces as the eye heals, but in some patients some
visual abnormalities may persist even after the fluid has
dissipated.3 Lasting visual symptoms can include localized
distortion, reduced color discrimination and decreased
night vision (likely caused by a disruption of the retinal
microarchitecture), subretinal fibrosis, and scarring or atro-
phy of the RPE.4–6 Poor visual recovery may be associated
with advanced age, multiple recurrences, persistent neuro-
sensory retinal detachment, retinal PED, or severe forms
of the disease that cause bullous retinal detachment. This
variant of CSC is an acute form that may develop sponta-
neously or following corticosteroid therapy, organ trans-
plantation, hemodialysis, or pregnancy. Bullous retinal
detachment is characterized by a serous or serofibrinous
subretinal exudation, and is thought to be due to an exag-
gerated breakdown of the permeability of the choriocapil-
laris, accompanied by single or multiple areas of RPE
decompensation, which allows fluid to gain access to the
subretinal space.7,8 The bullous retinal detachment usually
resolves slowly after many weeks or months of blurred
vision.
In most cases, CSC is acute (aCSC), with only a single
episode of illness occurring in the patient’s lifetime; how-
ever, it can be recurrent, and it can become chronic
(cCSC). A recurrence of aCSC may occur within 12
months in 30–50% of patients; it may then resolve again
spontaneously or continue to cause some vision distur-
bances. The chronic form, also known as Type II CSC,
occurs in approximately 5% of cases.
The definition of cCSC may be somewhat ambiguous
because it relies on a temporal criterion (the duration of
the serous retinal detachment), and on the presence of
extended RPE changes. The duration threshold above
which CSC is considered to be chronic varies among
different studies, from 3 to 6 months.9,10 Diffuse, rather
than focalized, abnormality of the RPE is exhibited in
cCSC, which produces persistent subretinal fluid. The
serous detachment in these cases tends to be shallower,
rather than dome shaped, in comparison with aCSC.
Persistence of serous retinal detachment in cCSC is
associated with progressive RPE decompensation and
deterioration of visual acuity.11,12
Diagnosis
Diagnosis of CSC usually begins with a standard exam-
ination of the retina, which shows central shallow serous
retinal detachment; this is confirmed by optical coherence
tomography (OCT), fluorescein and/or indocyanine green
(ICG) angiography, and optical coherence tomography
angiography (OCTA). The visual acuity of the affected
eye is usually slightly or moderately reduced due to the
decreased focal length caused by the raised retina; this
phenomenon makes the eye more hyperopic than before.
Use of an Amsler grid can be helpful to confirm sus-
pected macular edema in less overt cases and may help
localize the involved area of the visual field.13–15 The
morphologic changes that occur in eyes with aCSC are
formation of a limited bubble of central serous retinal
detachment (Figure 1), RPE detachment, and RPE
abnormalities.16,17 The outer retinal layers, which include
the photoreceptor layer, intermediate line, and inner seg-
ment/outer segment (IS-OS) junction, are well-visualized
and preserved; occasionally, thickened and hyperreflective
tips of detached photoreceptors may be noted. Less fre-
quent findings include focal protrusions of the RPE layer,
focal defects in the RPE at the leaking site, minutes
fibrinous exudate in the subretinal space, and subretinal
precipitates.15,18,19 Lastly, an increased choroidal thickness
associated with an increased choroidal vascular component
is well detectable with enhanced depth imaging (EDI)
OCT, predominantly in aCSC forms.20–23 The anatomical
resolution of subretinal fluid is concomitant with the nor-
malization of the choroidal thickness.24
The chronic form of CSC exhibits diffuse, rather than
focalized, abnormality of the RPE, producing persistent
subretinal fluid. The serous detachment in these cases
tends to be shallower rather than dome shaped in compar-
ison with aCSC. Changes in the RPE include low to flat
PED, the presence of micro-rips, hypertrophy and atrophy,
thickening of the deeper and thinning of the inner coroidal
layers, and thinned posterior surfaces of the detached
retina with hyperreflective detached photoreceptor tips. In
persistent cases, OCT reveals thinning of the outer retinal
layers corresponding to the photoreceptor layers, with poor
visualization of the IS-OS junction (Figure 2).14
Fluorescein and ICG angiography allow observation of
the fluid leakage from the choroidal vessels, the fluid
Semeraro et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
Clinical Ophthalmology 2019:132342
invasion into the subretinal space, and the choroidal blood
vessels. Typically, fluorescein angiography reveals one or
more fluorescent “pinpoints” indicating fluid leakage. An
expanding point of fluorescein leakage with late pooling
into a serous detachment (the classic “smokestack pat-
tern”) is visible in 10–15% of cases (Figure 3). If neuror-
etinal detachment persists, it tends to move toward the
lower part of the macula leading to depigmentation and
secondary decompensation of the inferior RPE, resulting
in the clinical appearance of gravitational atrophy of the
RPE.25
Indocyanine green angiography reveals focal delays
and hyperpermeability of the choroidal circulation,
revealing a delayed initial filling of choriocapillaris
arteries in the early phase, and dilation of the choriocapil-
laris veins leaking fluid in the subsequent phases. Use of
ICG angiography demonstrates that CSC is likely caused
by a primary dysfunction of the choriocapillaris; the fluid
build-up seems to occur due to small breaks in the RPE,
secondary to choriocapillaris disease.26
OCTA reveals areas of focal hypo- and hyper-perfusion
in the choriocapillaris. Though, due to the inability to
detect plasma flow, OCTA is not suitable to detect leakage
points in CSC with confidence. However, OCTA reliably
detects choroidal neovascularization (CNV) in CSC even
in the absence of exudative activity and may, therefore,
Figure 1 A spectral domain optical coherence tomography image of an eye affected by acute central serous chorioretinopathy showing a convex-shaped blister of fluid
separating the neurosensory retina from the retinal pigment epithelium and choroid.
Figure 2 A spectral domain optical coherence tomography image of an eye affected by chronic central serous chorioretinopathy showing a low level of subretinal fluid. At
the level of serous detachment, the inner limit is represented by the ellipsoid zone, with elevated photoreceptor tips, and marked reflectivity.
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represent an important supplement in the diagnosis of
CSC.24,27–29 Particularly, OCTA imaging revealed that
eyes with CNV complicating CSC exhibited significantly
lower choroidal vascular component compared to those
with CSC without CNV.30,31
Etiology and Pathophysiology
Stress Burden and Personality Traits
As previously discussed, CSC most often affects men who
are actively working, often as freelancers, managers, entre-
preneurs, or workers burdened by job responsibilities.
Psychological stress is considered one of the most impor-
tant risk factors for developing CSC. In 1986, Yannuzzi32
observed a strong association between CSC and the “Type-
A” personality pattern, or rather, the personality traits of
having a competitive drive, a sense of urgency, an aggres-
sive nature, and a hostile temperament. In a later report,
impulsiveness, emotional instability, overachievement, and
competitiveness were discussed as personality features
observed in CSC patients.33 More recently, the possible
association between CSC and the “narcissistic personality”
(characterized by an extreme gratification of self) was
suggested.34 During the past two decades, several indepen-
dent studies have shown that CSC occurs more frequently
in men with higher emotional distress35 a lower frustration
tolerance threshold33,36 and poor coping strategies for
stressful events.37,38 The presence of recent psychological
stress has been largely demonstrated as one of most impor-
tant CSC triggers.33,39–41 Resolution of the stressor may be
followed by symptomatic improvement in some cases.42
However, it is still a topic of debate whether stress mini-
mization (e.g., by psychological intervention or using beta-
blocker therapy) could prevent recurrences or progression
to chronic CSC. Interestingly, Type-A behavior and stress
are strongly linked to psychopharmacological medication
use43,44 and sleeping disturbances,45 which have also been
suggested as possible independent risk factors for CSC.41
Although the exact mechanisms are still poorly under-
stood, the link between CSC, personality traits, and stress
is proposed to be mediated through higher levels of circu-
lating stress hormones, particularly corticosteroids and
catecholamine.
Glucocorticoid Use
Many reports have suggested that high blood levels of
glucocorticoids (also called glucocorticosteroids, corticos-
teroids, or steroids), mineralocorticoids, and occasionally
testosterone are involved in the pathogenesis of CSC.
There is extensive evidence of an important effect of the
cortisol hormone on the capillary permeability of the chor-
oid, which may contribute to the underlying pathogenesis
of CSC.
Figure 3 Early and late fluorescein angiograms of a 29-year-old patient affected by chronic central serous chorio-retinopathy revealing an irregularity of the retinal pigment
epithelium, resembling a “honeycomb” pattern, near the point of fluorescein leakage. Window defects and late-phase leakage from the expanding point in the superior
macula are evident, toward the fovea in a “steam” configuration.
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Clinical studies on patients with Cushing syndrome,
which is characterized by abnormally high levels of corti-
sol, found concurrent CSC in 5–10% of cases. The
increased risk of CSC during pregnancy is also likely
driven by increased levels of endogenous corticosteroids,
as ocular dysfunction usually appears during the third
semester, but generally resolves spontaneously after deliv-
ery. Furthermore, abnormal cortisol elevation may explain
the association between CSC and erectile dysfunction,
which has been recently suggested by the authors of
a large case-control study.46
Endogenous cortisol levels are usually higher in patients
with CSC47 and the rate of urinary cortisol excretion is
increased.48 Exogenous systemic corticosteroids (e.g., cor-
tisone) are commonly used to treat inflammation and aller-
gies, but nasal corticosteroid sprays, eye drops, and topical
creams can also trigger CSC, aggravate it, and cause
relapses. Above all, inhalant/nasal, oral, and injectable ster-
oids seemed to be significant risk factors.41 Steroid-induced
CSC has less male predilection than idiopathic CSC, and
frequently has a bilateral presentation. Among solid organ
transplant patients receiving long-term corticosteroids,
those with renal transplants appear to be at a higher risk,
possibly due to underlying renal disease, hypertension,
microangiopathy, and previous exposure to hemodialysis,
all of which may modify choroidal hemodynamics.
The strong association between steroid use and CSC
may be identified by the RPE and choriocapillary receptor
reactivity during systemic corticosteroid treatment. Daruich
et al49 proposed that excess activation of the mineralocorti-
coid receptor (MR) in the choroidal endothelial cells, either
by aldosterone or glucocorticoids with a high affinity for the
MRs, induces upregulation of the vasodilator potassium
channel KCa2.3 that modulates smooth muscle relaxation
in the choroidal vessels. Systemic treatment with corticos-
teroids may damage the posterior blood-retinal barrier,
altering the permeability of the choriocapillaris and RPE,
resulting in focal areas of increased permeability that lead to
subretinal fluid accumulation.38 In contrast, mineralocorti-
coid antagonists reverse the upregulation of KCa2.3 chan-
nels in the choriod; this finding supports the use of MR
antagonists in CSC treatment.50
Catecholamines
Compared to healthy subjects, CSC patients present with
a significant sympathetic overactivation and decreased
parasympathetic activity, as observed by blood pressure
and heart rate variability.51 This may explain the
association between CSC and hypertension, as confirmed
by a recent meta-analysis.41 The use of sympathomimetic
agents, such as pseudoephedrine, oxymetazoline, ephedra
(found in bodybuilding/dietary products), and MMDA
(3-methoxy-4,5-methylenedioxyamphetamine, an illicit
amphetamine) has been associated with CSC.52,53
The development of CSC has also been noted after the
use of phosphodiesterase-5 inhibitors (such as sildenafil), but
there is conflicting evidence regarding CSC resolution after
treatment discontinuation.54 The autonomic nervous system
modulation of the choroidal blood flow may play an impor-
tant role in CSC pathogenesis, and it is consistent with the
damage induced by epinephrine on RPE cells in vitro.
Sleep Disturbances
Shift work and sleep disturbances have recently been
suggested as important independent risk factors for
CSC.40,41 Cortisol and catecholamine levels are controlled
by circadian regulation and can be deregulated in shift
workers, thereby contributing to CSC pathophysiology.
Other reasons for sleep disturbance were previously iden-
tified in CSC patients, including obstructive sleep apnea
(OSA). Early reports suggested that early diagnosis and
management of OSA could eventually reduce the risk of
CSC and preserve ocular function. Although several stu-
dies have shown a high prevalence of OSA in CSC
patients, there is still insufficient evidence to support
OSA screening in patients with CSC.52,55–57
Despite the strong association between sleep distur-
bance and CSC,41 there have been no studies evaluating
melatonin levels and rhythms in CSC patients. Melatonin
production is suppressed by light through melanopsin
ganglion cell activation during the day, and is typically
reduced in shift workers.58 Restoring sleep by reducing
stress or by using oral melatonin may, therefore, have
potential beneficial effects in patients with CSC.59
Other Factors
Infection with Helicobacter (H.) pylori may be
a predisposing factor for CSC. It appears that the presence
of these bacteria is correlated with the visual prognosis
and severity of the clinical manifestations of the disease.
Though the mechanism is still poorly understood, infection
with H. pylori allegedly creates an increased susceptibility
of the retinal tissue to oxidative stress generated by the
inflammation.
Patients suffering from kidney diseases, such as mem-
branoproliferative glomerulonephritis type II, may develop
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retinal abnormalities similar to CSC; this is likely caused
by choroidal deposits of the same material that originally
damaged the glomerular basement membrane in the
kidneys.
Genetic risk factors may also play a role in CSC,
possibly via the complement system; however, only very
rare familial cases have been reported thus far.60 Chronic
CSC is associated with genetic variants in ARMS2 and
CFH, indicating a genetic overlap between CSC and
AMD, otherwise alleles in ARMS2 and CFH that deter-
mines risk of AMD, may be protective for cCSC.
Chorioretinal Changes
Advances in imaging techniques, particularly ICG angio-
graphy, OCT and OCTA have led to a better understanding
of the pathophysiology of CSC.61 Clinical evidence from
multimodal imaging, such as choroidal congestion and
hyperpermeability with localized areas of choroidal non-
perfusion, suggests that choroidal dysfunction is an impor-
tant underlying cause of RPE dysfunction and subretinal
fluid leakage in CSC.62 The vascular hyperpermeability
and congestion belong to the pachychoroid vascular
changes that are believed to underlie the development of
focal alterations in the RPE, leading to the formation of
PED.30,63
Indocyanine green angiography has demonstrated lobular
choroidal ischemia and venous congestion with consequent
leakage of fluid from the choriocapillaris. The relative ische-
mia and increased hydrostatic pressure in the choroidal net-
work create secondary damage in the RPE that leads to the
breakdown of the external blood-retinal barrier, causing fluid
accumulation in the subretinal space.64 The subretinal fluid
originates from the choriocapillaris, not the vitreous, thus the
photoreceptors receive sufficient nourishment that allows
them to survive even during prolonged detachment. For this
reason, the patient’s vision is usually totally recovered, even
though the disease can last more than a month. However, if
the retina is detached for a long period, or if there is a bullous
retinal detachment with wide separation of the photorecep-
tors from the source of oxygen, which is the choriocapillaris,
ischemic damage of the photoreceptors may occur. This
damage subsequently leads to damage of the RPE via grav-
itational epitheliopathy. In cCSC, large areas of the RPE
decompensate, and central vision deteriorates. The detached
retina may also induce release of vascular endothelial growth
factor (VEGF) into the subretinal space, thereby delaying
spontaneous resolution and, in some cases, lead to
a subretinal choroidal neovascularization.4,65
Therapy
The prognosis for resolution and visual recovery in
patients with aCSC is usually good, thus observation and
patient reassurance is considered the best treatment course.
Positive converging lenses can be used to improve visual
acuity until CSC resolves. Most affected patients recover
spontaneously with improvement of visual acuity, reat-
tachment of the sensory retina, and improvement of the
other symptoms within 3–4 months.3 Conversely, approxi-
mately 20–30% of patients will develop one or more
recurrences of aCSC, and 5% will develop cCSC.
A significant number of these patients develop a limited
area of RPE atrophy and depigmentation after resolution
of the affected retinal area.
For patients with CSC, it is important to suspend, or
replace with an alternative, any current medications con-
taining steroids, including creams, sprays, and eye drops.
In patients treated with corticosteroids, only suspension of
this therapy will be effective in reducing the bullous retinal
detachment.
Faster regression of subretinal exudation may be obtained
using laser photocoagulation applied to close focal sites of
RPE leakage, or by photodynamic therapy (PDT) applied to
the areas of choroidal vascular hyperpermeability.
However, a recent meta-analysis concerning the ther-
apeutic interventions for aCSC analyzed 25 randomized
clinical trials (RCTs) concluded that it is not completely
clear whether a clinically important benefit exists to treat-
ing aCSC since it often resolves spontaneously.66
Nevertheless, treatment should be considered if resorption
does not occur within 3–4 months and in cases of aCSC
recurrence in eyes that sustained a permanent visual deficit
from a previous episode. Treatment is also suggested in
bilateral cases of aCSC, in cases with reduced visual
acuity in the fellow eye, and in patients that absolutely
require prompt restoration of their vision owing to occu-
pational necessity. The majority of ophthalmologists
recommend treatment of cCSC.10,67–71
Before the advent of photodynamic therapy, the only
treatment option for patients with aCSC was conventional
argon laser focal photocoagulation applied to close focal
sites of RPE leakage. It consists of light laser treatment that
may be applied directly to the point of angiographic leakage
if it is located no more than 400 µm from the fovea. Laser
treatment consists of a few spots (3–5 impacts) of small
diameter (100 µm), low intensity (100–150 mWatt, so as to
achieve a slight whitening of the retina), and short pulse
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duration (100 mSec).72 The laser treatment induces scar
tissue formation on the RPE, while coagulating the cluster
of diseased RPE cells. It is plausible that the scar restores
the RPE barrier to further subretinal fluid accumulation,
allowing the pump function of the surrounding healthy
epithelium to return the fluid to the choriocapillaris.73
Argon laser treatment of the leakage point of the RPE
accelerates visual recovery, even though it does not likely
improve the final visual outcome significantly. Only
selected cases of aCSC may be treated with conventional
argon laser therapy; for many cases the leak is too close to
the central macula where photocoagulation would leave
a blind spot, or the leakage is too widespread, and its source
is difficult to identify. More recently, navigated laser photo-
coagulation (Navilas® System; GmbH, Teltow, Germany)
has improved accuracy and comfort for retinal laser photo-
coagulation for various retinovascular diseases.74,75 In par-
ticular, navigated laser photocoagulation, due to its ability
of eye tracking and laser planning on the fluorescein angio-
graphy on the same device, can perform precise targeted
treatments thereby reducing iatrogenic retinal damage.76
Photodynamic therapy was introduced as an off-label
treatment for both aCSC and cCSC approximately 10
years ago and is applied to the areas of choroidal vascular
hyperpermeability. PDT utilizes verteporfin (trade name,
Visudyne; Novartis AG, Switzerland), a photosensitive
dye that accumulates in abnormal blood vessels. When
stimulated by a nonthermal red laser light with
a wavelength of 689 nm, the presence of oxygen produces
many oxygen radicals resulting in local damage to the
endothelium and blockage of the abnormal vessels.77,78
After the dye infusion, a laser fluence of 50 J/cm2 is
directed at the surface of the damaged areas to activate
the verteporfin, which triggers a healing mechanism both
in the damaged choroidal vessels and RPE. Exploiting the
mechanism of causing oxidative damage to the abnormal
vessels of the choriocapillaris, PDT induces the absorption
of the subretinal fluid and choroidal vascular remodeling
with reduction of choroidal hyperpermeability.79 The effi-
cacy of this treatment, however, is questionable since PDT
is suspected of causing choriocapillaris closure and RPE
alterations with subsequent damage to the photoreceptors.
In addition, PDT may also stimulate the upregulation of
VEGF and choroidal neovascularization.80,81 In recent
years, various adjustments to the fluence and verteporfin
dosage have gained good quality evidence demonstrating
a low incidence of adverse effects with this CSC treat-
ment. To reduce PDT toxicity, half-dose PDT, low-dose
PDT, and reduced-fluence PDT were introduced.82 The
standard dose of administered verteporfin is 6 mg/m2;
a reduced dose of 3 mg/m2 (half-dose PDT) has been
proposed to treat CSC.10,12,83 A lower dose of 2 mg/m2
(⅓- dose PDT) was tested, but appeared less effective.84
Reduced or half-fluence PDT consists of reducing of the
laser fluence to 25 J/cm2 instead of the standard 50 J/
cm2.68 Half-dose and half-fluence PDT have shown little
difference in efficacy, and no difference in safety when
compared to treatment with the standard/full doses. Nicolò
et al85 performed a retrospective study comparing half-
fluence and half-dose PDT, and concluded that half-dose
PDT seems to induce a longer duration of effects in
patients with cCSC than half-fluence PDT.
Despite its effectiveness, PDT is not practical in most
countries owing to economic reasons. Transpupillary ther-
motherapy (TTT) is a less expensive therapeutic option; it
uses a lower temperature than that of conventional laser
photocoagulation, which minimizes permanent retinal and
choroidal damage. Recently, this therapy was introduced
to accelerate the resolution of CSC.86,87 The mechanism
by which TTT leads to the repair of RPE damage is not yet
completely understood.88
Similarly, subthreshold micropulse laser (SML) ther-
apy is a new treatment that controls the thermal elevation
induced by conventional continuous wave laser photocoa-
gulation. Treatment with an SML reduces the thermal
elevation by “chopping” a continuous wave beam into
a train of repetitive short pulses, which allows the tissue
to cool between pulses, thereby reducing thermal buildup.
The rise in temperature in the target tissue remains sub-
lethal, but it is able to create a stress response which
induces anti-angiogenic effects. Therapy with an SML
consists of using a grid to apply micropulsed laser burst
to the retinal tissue that cause an approximate 7-°C
increase in temperature with each 100-microsecond
micropulse.89–91 This therapy has been applied to the
retina using different lasers with different wavelengths
(810, 532, and 577 nm), and it seems that thermal eleva-
tion of the retina induces the release of a group of mole-
cules known as heat shock proteins (HSPs),90 which are
involved in repairing RPE cells and in reducing the inflam-
matory cascade.92 Recently, in comparison to half-dose
PDT, the application of 577-nm SML treatment resulted
in a slightly greater reduction of the subretinal fluid in
patients with chronic CSC.93
A similar mechanism of action (sub-lethal thermal
effect) has been proposed by Russo et al94 using an
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infrared laser light of 689 nm (the same laser utilized for
PDT), and has shown promising clinical results. They
evaluated the photothermal effect of near-infrared 689-
nm laser treatment (689-LT) versus half-dose verteporfin
PDT (hd-PDT) for the treatment of cCSC. Both treatment
groups showed significant improvement in BCVA, as well
as reductions in central retinal and subfoveal choroidal
thickness. Although hd-PDT led to a faster reduction in
central retinal thickness, no significant differences were
recorded between the groups for any other measured para-
meter at any time point. The authors thereby concluded
that both hd-PDT and 689-LT were effective for treating
cCSC, and speculated that the thermal effect stimulating
the expression of HSPs may potentially explain the favor-
able effect of the non-lethal continuous wave 689-LT.
Specifically, this near-infrared laser treatment, delivering
95 J/cm2 via an intensity application of 805 mW/cm2 over
118 seconds, produces a photothermal effect that heats the
RPE, potentially eliciting the production of HSPs as
a form of TTT.
Additionally, intravitreal injections of anti-VEGF drugs
have been used, off-label, for the treatment of aCSC. This
group of drugs effectively reduces choroidal hyperperme-
ability by blocking vascular leakage. Choroidal hyperper-
meability is often associated with increased expression of
VEGF, although high VEGF levels are not detected in the
aqueous humor of CSC patients. Many reports have
demonstrated that therapy with anti-VEGF drugs is effec-
tive, with good functional short-term outcomes for treat-
ment of acute and chronic CSC.95,96 However, during the
middle-long term period (six months), low-fluence PDT
treatment is more effective than intravitreal anti-VEGF
therapy in reducing the subretinal fluid in patients affected
by CSC.97 Semeraro et al82 compared intravitreal bevaci-
zumab, a recombinant humanized monoclonal antibody
that inhibits the biologic activity of VEGF and prevents
binding of VEGF to its receptors on the surface of
endothelial cells, with low-fluence PDT in patients with
cCSC. In a series of 22 patients, no statistically significant
difference could be identified between the two treatment
groups after 9 months of follow-up; therefore, they con-
cluded that intravitreal bevacizumab may be a valid treat-
ment option for treating cCSC.82 A recent meta-analysis of
6-month studies showed that patients affected by aCSC
who were treated with anti-VEGF drug injections had
significantly better BCVA than the observation group at
the 1-month follow-up appointment; however, no signifi-
cant difference was observed for longer follow-up times.98
Finally, numerous orally administered drugs have been
proposed to treat CSC, including acetazolamide and other
diuretics, mineralocorticoid antagonists (spironolactone
and eplerenone), 5-alpha reductase inhibitors (finasteride),
aspirin, beta-blockers, vitamins, and nonsteroidal anti-
inflammatory medications.99 All these drugs were found
to be mostly effective in animal and in vitro studies, but
none have been shown to have unequivocal benefits in
humans.6,82
Supporting the hypothesis of the role of mineralocorti-
coids on the pathogenesis of CSC, oral spironolactone and
eplerenone have recently been proposed as a treatment
option for CSC.100–102 Eplerenone acts as a competitive
antagonist of the mineralocorticoid receptors that may be
active in modulating local permeability in cCSC patients.
In three case series treatment with spironolactone and
eplerenone resulted in a significant reduction in central
macular thickness and submacular fluid in patients with
non-resolving cCSC.100–102 These drugs seemed to be
beneficial and well-tolerated in half of the patients, and
a complete resolution of the subretinal fluid 6 months after
treatment initiation occurred.49 In non-randomized studies,
treatment with carbonic anhydrase inhibitors (e.g., aceta-
zolamide) has been shown to reduce the duration of CSC,
but without significant effect on final visual
recovery.103,104 Treatment with finasteride, an inhibitor of
dihydrotestosterone synthesis, was evaluated in a small
series of 5 patients affected by cCSC. Macular thickness
and subretinal fluid accumulation diminished during the
treatment period, but CSC unfortunately recurred immedi-
ately upon planned cessation of the medication105.
Conclusion
Central serous chorioretinopathy is an enigmatic disease
that is still not completely understood due to its multi-
factorial etiology, complex pathogenesis, and wide sys-
temic associations. No single treatment has provided
overwhelming evidence of efficacy in published RCTs.66
However, the majority of these studies possess many lim-
itations, specifically a relatively small number of partici-
pants and short follow-up periods.
Furthermore, it is not still clear whether there it is
clinically beneficial to treat aCSC since it often resolves
spontaneously as part of its natural progression. Some
studies have suggested that early intervention (within 3
months) results in better visual outcomes, other than
a timely treatment did not induce a significant difference
in long-term visual acuity.106–109 Currently, approximately
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79.1% of ophthalmologists tend to observe cases of aCSC,
whereas for chronic cases, 66.7% use PDT, with the
majority preferring half-fluence PDT.110 Based on our
knowledge regarding CSC pathogenesis, it seems that the
best treatment approach for this disease is individualized
therapy. Factors that may prompt earlier treatment include
the following: recurrent CSC, the patient’s demands,
a massive serous detachment, or a history of poor response
in the fellow eye to initial observation.111
A greater understanding of the pathophysiology of
CSC could be provided by future studies using newer
imaging techniques, such as optical coherence tomography
angiography, which could provide more information as to
the reactivity of the choriocapillaris to drugs and other
therapies that affect choroidal vessel permeability.112
Method of Literature Search
Articles providing data on central serous chorioretinopathy
were found by searching PubMed and Google Scholar
with the following MESH terms: “central serous chorior-
etinopathy.” Additional search terms included “central ser-
ous retinopathy, central serous choroidopathy.” Case
reports were considered only if they provided novel infor-
mation beyond that already covered in reviews.
Publications cited in articles selected by searches were
also retrieved. Only articles in English were reviewed,
and the full publication was retrieved. No restrictions
were applied to the date of publications, which span
from 1900 to 2017.
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